Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.

p53 Mutations in Human Cancers

1991 • 8,133 citations

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

1994 • 5,204 citations

The Dendritic Cell System and its Role in Immunogenicity

1991 • 4,733 citations

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

1996 • 849 citations

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.

1996 • 746 citations

Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.

1979 • 736 citations

Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer.

1996 • 708 citations

T cell defined tumor antigens

1997 • 641 citations

Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer

1982 • 448 citations

Targeting p53 as a general tumor antigen.

1995 • 315 citations

Dendritic Cells in Antitumor Immune Responses

1996 • 282 citations

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

1993 • 267 citations

Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes

1997 • 264 citations

Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.

1996 • 262 citations

Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells.

1987 • 237 citations

Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer

1994 • 235 citations

Dendritic Cells in Antitumor Immune Responses

1996 • 219 citations

Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.

1998 • 179 citations

A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.

1993 • 171 citations

Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.

1995 • 157 citations

Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide

1996 • 155 citations

MDM2-arbiter of p53's destruction

1997 • 127 citations

The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope

1998 • 124 citations

Genetically modified bone marrow‐derived dendritic cells expressing tumor‐associated viral or “self” antigens induce antitumor immunity in vivo

1997 • 120 citations

Accumulation of the p53 Protein Allows Recognition by Human CTL of a Wild-Type p53 Epitope Presented by Breast Carcinomas and Melanomas

1998 • 118 citations

Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.

1995 • 115 citations

IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro.

1996 • 111 citations

The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy

1996 • 109 citations

p53, a potential target for tumor-directed T cells

1994 • 88 citations

Flow-cytometric determination of peptide-class I complex formation identification of p53 peptides that bind to HLA-A2

1994 • 81 citations

HLA and cancer: from research to clinical impact

1998 • 77 citations

Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells

1993 • 74 citations

Identification of wild‐type and mutant p53 peptides binding to HLA‐A2 assessed by a peptide loading‐deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay

1994 • 72 citations

A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein.

1996 • 64 citations

Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif.

1994 • 62 citations

p53-Based Immunotherapy of Cancer

1998 • 61 citations

Molecular mimicry reflected through database screening: serendipity or survival strategy?

1996 • 53 citations

HLA restriction and T‐cell‐receptor Vβ gene expression of cytotoxic T lymphocytes reactive with human squamous‐cell carcinoma of the head and neck

1994 • 36 citations

T Cell-Mediated Cytotoxicity Against p53-Protein Derived Peptides in Bulk and Limiting Dilution Cultures of Healthy Donors

1995 • 31 citations

In Vitro Expansion of Tumor-Specific, HLA-Restricted Human CD8+ Cytolytic T Lymphocytes

1994 • 18 citations

Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract

1995 • 17 citations

MUTANT p53 AS A TARGET FOR IMMUNE RECOGNITION

1992 • 1 citations